Cadila Healthcare Limited Announces Unaudited Consolidated and Parent Earnings Results for the Third Quarter and Nine Months Ended December 31, 2016; Provides CapEx Guidance for the Full Year 2017
January 31, 2017 at 06:46 am
Share
Cadila Healthcare Limited announced unaudited consolidated and parent earnings results for the third quarter and nine months ended December 31, 2016. For the quarter, on consolidated basis, the company's total income from operations was INR 23,638 million compared with INR 24,089 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 3,145 million compared with INR 5,177 million a year ago. Profit from ordinary activities before tax was INR 3,244 million compared with INR 5,370 million a year ago. Net profit was INR 2,740 million or INR 2.75 per basic and diluted share compared with INR 4,464 million or INR 4.21 per basic and diluted share a year ago. Earnings before interest, depreciation and tax, which is the EBITDA, was down 32% year-on-year to INR 4.04 billion.
For the nine months, on consolidated basis, the company's total income from operations was INR 71,004 million compared with INR 72,299 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 11,795 million compared with INR 15,646 million a year ago. Profit from ordinary activities before tax was INR 11,996 million compared with INR 16,006 million a year ago. Net profit was INR 9,458 million or INR 9.53 per basic and diluted share compared with INR 13,605 million or INR 13.34 per basic and diluted share a year ago.
For the quarter, on parent basis, the company's total income from operations was INR 11,287 million compared with INR 17,829 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 150 million compared with INR 5,638 million a year ago. Profit from ordinary activities before tax was INR 634 million compared with INR 5,894 million a year ago. Net profit was INR 539 million or INR 0.53 per basic and diluted share compared with INR 4,839 million or INR 4.73 per basic and diluted share a year ago.
For the nine months, on parent basis, the company's total income from operations was INR 35,410 million compared with INR 56,727 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 2,377 million compared with INR 19,553 million a year ago. Profit from ordinary activities before tax was INR 4,023 million compared with INR 20,511 million a year ago. Net profit was INR 3,280 million or INR 3.20 per basic and diluted share compared with INR 16,836 million or INR 16.45 per basic and diluted share a year ago.
The company expects full year CapEx to be roughly INR 10 billion, plus M&A.
Zydus Lifesciences Limited is an India-based global life sciences company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The Company is engaged in the business of integrated pharmaceutical operations. Its product portfolio includes active pharmaceutical ingredients (API), human formulations, animal health and veterinary, health, and wellness products. Its products include India formulations, Generics and Zydus biologics. The Company's products include Lipaglyn and Bilypsa (Saroglitazar), Ujvira (Trastuzumab emtansine biosimilar), Exemptia (Adalimumab biosimilar), Vivitra (Trastuzumab biosimilar) and Bryxta (Bevacizumab biosimilar). Its Zydus biologics covers various therapeutic areas, such as oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology and infectious illnesses, among others. The Company has a global presence and markets its products in the United States, India, Europe and emerging markets.
Cadila Healthcare Limited Announces Unaudited Consolidated and Parent Earnings Results for the Third Quarter and Nine Months Ended December 31, 2016; Provides CapEx Guidance for the Full Year 2017